LXRX- Lexicon Pharmaceuticals, Inc.

Name: Lexicon Pharmaceuticals, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Lexicon Pharmaceuticals, Inc. (LXRX) has 15 insiders with recent SEC Form 4 filings, including 12 buys and 0 sells. LXRX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
Dir	Debbane Raymond	1.91M	$3.20M	-
CEO	Exton Michael	503.3K	$845.5K	-
VP	Crum Brian T	363.7K	$610.9K	-
VP	Granowitz Craig B	323.4K	$543.4K	-
VP	Defrancesco Lisa	256.4K	$430.7K	-

Activity

Buys and sells only

Transactions

10 filings · page 2

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jun 26, 2023	Coats Lonnel	Chief Executive Officer	Buy	20,000	$2.34	$46,742.00	+1.3%	-51.2%	-21.7%
Jun 23, 2023	McDermott Wendy	VP, Human Resources	Buy	10,000	$2.43	$24,300.00	+80.1%	-52.3%	-21.9%
Jun 22, 2023	Coats Lonnel	Chief Executive Officer	Buy	40,000	$2.31	$92,400.00	+5.4%	-50.0%	-20.3%
Jun 20, 2023	Wade Jeffrey L	President And CFO	Buy	12,000	$2.33	$28,000.00	+2.4%	-48.1%	-25.8%
Jun 5, 2023	Artal International S.c.a.47	Director, 10% Owner	Buy	27,775,050	$2.60	$72,215,130.00	+54.6%	-35.4%	-30.7%
Aug 5, 2022	Invus Us Partners LLC	Director, 10% Owner	Buy	147,390	$2.50	$368,475.00	+2.8%	-24.4%	-33.9%
Aug 5, 2022	Artal International S.c.a.47	Director, 10% Owner	Buy	2,426,070	$2.50	$6,065,175.00	+5.0%	-24.4%	-33.9%
Aug 1, 2022	Artal International S.c.a.47	Director, 10% Owner	Buy	16,173,800	$2.50	$40,434,500.00	+50.1%	-9.3%	-18.1%
Aug 1, 2022	Invus Us Partners LLC	Director, 10% Owner	Buy	982,600	$2.50	$2,456,500.00	+22.7%	-9.3%	-18.1%
Aug 1, 2022	Debbane Raymond65	Director	Buy	982,600	$2.50	$2,456,500.00	+22.7%	-9.3%	-18.1%

← PrevPage 2Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC